Trulieve Cannabis is trading 4.1% down at $10.42 as a DEA judge’s pause in federal cannabis rescheduling weighs on the sector.
- The delay has reset expectations for regulatory timing.
- Shares fell sharply in the prior session, and sector peers were also under pressure.
- Broader markets were higher on softer-than-expected September payrolls and easing rate-hike expectations; no distinct Trulieve-specific announcement explaining the October 2 move surfaced.